Deferred Research And Development Arrangement (Details) - USD ($) |
3 Months Ended | 9 Months Ended | 12 Months Ended | ||
---|---|---|---|---|---|
Sep. 30, 2017 |
Sep. 30, 2018 |
Sep. 30, 2017 |
Dec. 31, 2003 |
Feb. 05, 2018 |
|
Research and Development Arrangement, Contract to Perform for Others [Line Items] | |||||
Other income | $ 368,750 | ||||
Percentage of licensing revenue | 50.00% | ||||
Rexgene Biotech Co., Ltd. [Member] | |||||
Research and Development Arrangement, Contract to Perform for Others [Line Items] | |||||
Research and development arrangement, one-time fee | $ 1,500,000 | ||||
Reduction of research and development expenses | $ 18,750 | $ 6,250 | $ 56,250 | ||
Research and development period | 20 years | ||||
Other income | $ 368,750 | ||||
Maximum [Member] | |||||
Research and Development Arrangement, Contract to Perform for Others [Line Items] | |||||
Licensing revenue agreement | $ 5,000,000 |
X | ||||||||||
- Definition Licensing Revenue Agreement No definition available.
|
X | ||||||||||
- Definition Licensing Revenue Agreement, Percent No definition available.
|
X | ||||||||||
- Definition Research And Developement Agreement Period No definition available.
|
X | ||||||||||
- Definition Research And Developement Agreement Period Expense Reduction Amount No definition available.
|
X | ||||||||||
- Definition Amount of income related to nonoperating activities, classified as other. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|